Perspectives

Life sciences research and development insights

Opportunities to improve the patient experience and R&D productivity

Clinical innovation remains imperative amid increasing pricing pressures, growing market share for generic pharmaceuticals and biosimilars, looming patent cliffs, and heightened scrutiny by regulators. With many new avenues enabled by the 21st Century Cures Act, real-world evidence, translational medicine, big data analytics, and digital technologies, new opportunities abound–if strategically harnessed–to enhance the patent experience and improve R&D efficiencies and returns.

Join the Digital R&D: Engaging patients, innovating care Dbrief

August 22 | 1 p.m. ET | 17:00 GMT

The future of real-world evidence

Many biopharma companies are increasingly using real-world evidence (RWE)—clinical evidence about a product’s usage, potential benefits, and risks derived from real-world data (RWD)—not only to demonstrate the value of their products but increasingly to address regulatory requirements, drive drug development, support outcomes-based contracts, and reduce products’ time to market. Deloitte’s annual RWE benchmarking survey (the inaugural edition published in 2017) studies how these companies are using RWE, what they are investing in, areas of impact, and the hurdles to successful adoption.
 

Digital R&D

Digital R&D: Transforming clinical development

The Deloitte Center for Health Solutions interviewed 43 leaders across the clinical-development ecosystem to understand how digital technologies are being used (or not) by biopharmaceutical firms. The findings focus on understanding the relatively slow adoption of digital technologies in clinical development and opportunities technology offers biopharma to develop better patient experiences, deeper insights and faster cycle times for future therapies.

Read more on Deloitte’s Digital R&D Insights:

Measuring the return from pharmaceutical innovation 2017: Can emerging technology help biopharma improve the returns on R&D?

The eighth annual pharmaceutical innovation study, a collaboration between Deloitte’s US & UK Centers for Health Solutions, looks at the state of R&D in the biopharma industry and estimates the return on investment that 12 large-cap biopharma companies may expect to achieve. The report also includes an extension cohort of four mid-tier biopharma companies.

Key findings for top 12 large-cap biopharma

  • R&D returns have declined to 3.2 percent, down from 10.1 percent in 2010
  • It now costs these companies almost $2bn to bring a drug to market
  • Projected peak sales per asset decreased by more than half between 2010 and 2016 but have increased by 18 percent in 2017

Emerging technology and new drug development paradigms offer promise
Biopharma companies are just starting to experiment with emerging technologies, and early adopters will reap the rewards of a much more efficient R&D process, improving both the quality of assets and the time and cost it takes to get them to market. The study explores how augmented intelligence, real world evidence, robotics and cognitive automation and other digital technologies, including social media, mHealth, wearables, connected devices, and telemedicine, can help transform how drugs are discovered, developed and brought to patients.

Read the related "My Take" article: Can emerging technology help biopharma improve the returns on R&D?

Intellectual property theft prevention in life sciences: Managing the risks for information security

The pressures on life sciences companies to innovate faster and improve return on investment have increased dependence on digital information, network-based information sharing, new connected relationships with consumers, and new forms of collaboration with third parties (such as external research organizations). These trends have widened the risk aperture.

Where cyber-related regulations haven’t forced strong cybersecurity investments, a life sciences company’s defenses and ability to detect and respond to attacks can be very weak, especially relative to the value of the IP it’s holding. It is time for organizations to up the ante and significantly alter the odds of becoming a victim.

Getting real with real-world evidence (RWE): 2017 RWE benchmark survey

The bipartisan 21st Century Cures Act , signed by President Obama towards the end of his term in December 2016, charges the Food and Drug Administration (FDA) with evaluating the expanded use of RWE, including its potential to support the approval of new indications for previously approved drugs.

Deloitte’s 2017 real world evidence benchmark survey shows that life sciences companies are making some progress in using RWE but still have opportunities to expand applications across the value chain, consider new channels to access real world data (RWD), and improve their overall capabilities.

Download the survey findings

Contact us to receive the 2018 results

Did you find this useful?